(NASDAQ: STRO) Sutro Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.38%.
Sutro Biopharma's earnings in 2026 is -$153,602,000.On average, 14 Wall Street analysts forecast STRO's earnings for 2026 to be -$149,228,403, with the lowest STRO earnings forecast at -$255,602,336, and the highest STRO earnings forecast at -$18,268,909. On average, 13 Wall Street analysts forecast STRO's earnings for 2027 to be -$138,477,502, with the lowest STRO earnings forecast at -$188,859,921, and the highest STRO earnings forecast at -$79,339,262.
In 2028, STRO is forecast to generate -$138,958,044 in earnings, with the lowest earnings forecast at -$167,262,011 and the highest earnings forecast at -$87,342,784.